DIA vs XBI
SPDR Dow Jones Industrial Average ETF vs SPDR S&P Biotech ETF
- • DIA has the lower expense ratio at 0.16% vs 0.35% for XBI.
- • DIA pays a higher dividend yield (1.39%).
Side-by-side metrics
| Metric | DIA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.16% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.39% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $45.14B | $10.92B |
YTD return | 10.11% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.85 | 1.01 |
P/E ratio | 20.74 | — |
Last price | $523.59 | $156.41 |
Inception | — | — |
Issuer | State Street | State Street |
DIA top holdings
| GS | The Goldman Sachs Group Inc | 10.26% |
| CAT | Caterpillar Inc | 7.14% |
| MSFT | Microsoft Corp | 5.99% |
| AMGN | Amgen Inc | 5.35% |
| V | Visa Inc Class A | 4.74% |
| UNH | UnitedHealth Group Inc | 4.67% |
| TRV | The Travelers Companies Inc | 4.55% |
| AAPL | Apple Inc | 3.95% |
| JPM | JPMorgan Chase & Co | 3.87% |
| SHW | Sherwin-Williams Co | 3.82% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About DIA
DIA (SPDR Dow Jones Industrial Average ETF) is Tracks the 30-stock Dow Jones Industrial Average. Managed by State Street, the fund carries $45.1B in assets under management, an expense ratio of 0.16%, a dividend yield of 1.39%. Its largest holding is The Goldman Sachs Group Inc (GS), which represents 10.3% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.